E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Urolithiasis and secondary hyperoxaluria |
|
E.1.1.1 | Medical condition in easily understood language |
Kidney stones and increased urinary oxalate output |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Symptoms and general pathology [C23] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Primary objective: to investigate whether the administration of Lanthanum Carbonate at a dose of 750 mg daily reduces the urinary oxalate excretion in patients with secondary hyperoxaluria and nephrolithiasis. |
|
E.2.2 | Secondary objectives of the trial |
Secondary objectives
- to investigate whether a dose increase from 750 to 1500 mg Lanthanum Carbonate daily results in a significant decrease in urinary oxalate excretion
- to investigate the effect of Lanthanum Carbonate on serum phosphorus and urinary phosphorus excretion
- to evaluate the effect of Lanthanum Carbonate on serum calcium and urinary calcium excretion
- to assess the evolution of serum Lanthanum levels
- to assess the safety of Lanthanum Carbonate
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Patients aged 18 years or older
Willing to give Informed Consent
eGFR > 60 ml/min/1m²73 (CKD-EPI Formula)
Hyperoxaluaria (defined as urinary oxalate > 45 mg/24 hours), demonstrated on 24-hour urine collection within 18 months prior to baseline visit
History of nephrolithiasis |
|
E.4 | Principal exclusion criteria |
Allergy to Lanthanum Carbonate
Hypophosphateamia at baseline (< 0.81 mmol/L)
Severe known liver insufficiency
Pregnancy
Breast feeding
Female participant of childbearing potential unwilling to take efficient contraceptive measures for the duration of the study |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The mean reduction in urinary oxalate excretion in patients treated with a daily Lanthanum Carbonate dose of 750 mg, expressed in mg/24 hours and as urinary oxalate to creatinine ratio, expressed in mg oxalate/g creatinine. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
After first 2-week experimental period (between days 12 and 14)
|
|
E.5.2 | Secondary end point(s) |
The incremental reduction in urinary oxalate excretion after doubling of the dose of Lanthanum Carbonate from 750 mg to 1500 mg daily, expressed in mg/24 hours and as urinary oxalate to creatinine ratio, expressed in mg oxalate/g creatinine
The proportion of patients developing severe hypophosphatemia after the first and after the second treatment period, defined as serum phosphorus < 0.64 mmol/L
The evolution of phosphaturia during the study, evaluated by
- 24-hour urinary phosphorus excretion, expressed in mmol/24 hours
- urinary phosphorus to creatinine ratio, expressed in mmol phosphorus/g creatinine
- fractional excretion of phosphorus , expressed in %, defined as (urinary phosphorus (mmol/L) x serum creatinine (mg/dL)) / (serum phosphorus (mmol/L) x urine creatinine (mg/dL))
The proportion of patients developing hypophosphaturia after the first and after the second treatment period, defined as urinary phosphorus < 12.9 mmol/24 hours
The evolution of calcemia during the study, expressed in mmol/L (with serum calcium corrected for the serum albumin concentration according to the formula: corrected calcium (mmol/L) = measured calcium (mmol/L) + 0.02 x (40 - albumin (g/L))
The evolution of calciuria during the study, evaluated by
- 24-hour urinary calcium excretion, expressed in mmol/24 hours
- urinary calcium to creatinine ratio, expressed in mmol calcium/g creatinine
- fractional excretion of calcium, expressed in % defined as (urinary calcium (mmol/L) x serum creatinine (mg/dL)) / (serum calcium(mmol/L) x urine creatinine (mg/dL)), with serum calcium corrected for the serum albumin concentration according to the formula: corrected calcium (mmol/L) = measured calcium (mmol/L) + 0.02 x (40 - albumin (g/L))
The evolution of mean serum La levels, expressed in mcg/L
The number and the proportion of patients experiencing adverse events
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
After first 2-week treatment period (between days 12 and 14)
After second 2-week treatment period (between days 26 and 28)
28 days after last Lanthanum Carbonate administration (between days 54 and 56) |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | Yes |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | Yes |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |